Krystexxa (Pegloticase) Cost in 2026, and How to Lower It
Krystexxa (pegloticase) for chronic gout runs about $5,200 to $6,000 per infusion, given every two weeks, so a full course of roughly six months totals about $67,000 to $82,000. The levers that matter most are the manufacturer’s assistance programs, a lower-cost infusion site, and your out-of-pocket maximum.
- Krystexxa is 8 mg IV every 2 weeks (billed under J-code J2507), so the cost is a repeating charge across the course, not a one-time bill.
- Amgen makes Krystexxa and runs both a copay program (commercial insurance) and the Amgen Safety Net Foundation free-drug program (uninsured/underinsured under an income limit).
- Site of care still applies: a standalone infusion center or doctor’s office avoids the hospital facility fee added on top of the drug.
What Krystexxa Costs
These are national estimates. What you personally owe depends on your insurance, your out-of-pocket maximum, and any assistance you use.
| What | Typical amount |
|---|---|
| Per infusion (drug) | ~$5,200 to $6,000 |
| Full course (~6 months) | ~$67,000 to $82,000 |
| Your out-of-pocket, insured | up to your OOP max |
| With manufacturer assistance | as low as $0 |
Krystexxa is often given with a medication (like methotrexate) to reduce reactions and improve response, which can add small costs but is a clinical decision by your prescriber.
Already got a bill for your Krystexxa (pegloticase) infusion? Check if you were overcharged.
A typical Krystexxa (pegloticase) infusion runs $5,200 to $6,000 without insurance. Enter what you were charged and we will flag it.
Or send us the bill and we will fight it down. 64% of cases reduced.
How to Lower the Cost
Use the manufacturer program that fits your coverage
Commercially insured patients can use the Amgen copay program to cut coinsurance. Uninsured or underinsured patients under an income limit may get Krystexxa free through the Amgen Safety Net Foundation. On Medicare, use an independent gout charity fund instead. Our help paying for medication tool points you to the right one.
Choose a lower-cost infusion site
A standalone infusion center or doctor’s office avoids the hospital facility fee. Ask your prescriber whether your infusions can be given there instead of a hospital outpatient department.
Confirm prior authorization before the first dose
Krystexxa almost always requires prior authorization. Confirm it is approved before you start, because a denial mid-course can leave you with unexpected bills for infusions already given.
Have the bill reviewed across the course
Over a dozen infusions, small errors add up: wrong J-code units, duplicate facility fees, or an out-of-network site. CareRoute Bill Defense reviews the bills and disputes errors, with no fee unless we save you money.
Frequently Asked Questions
How much does Krystexxa cost?
About $5,200 to $6,000 per infusion, given every two weeks, so a full course of roughly six months totals about $67,000 to $82,000 before insurance. Insured patients usually pay only up to their annual out-of-pocket maximum, and manufacturer assistance can lower it further.
Is there help paying for Krystexxa?
Yes. Amgen, which makes Krystexxa, runs a copay program for commercially insured patients and the Amgen Safety Net Foundation, which provides the drug free to uninsured or underinsured patients under an income limit. Medicare patients cannot use copay cards but can use independent charity funds. Which one fits depends on your insurance and income.
I have insurance. Why is my share still large?
Because each infusion is expensive and there are many, your coinsurance can add up fast, often reaching your entire annual out-of-pocket maximum early in the course. After that, in-network covered care is paid at 100% for the rest of the year. A copay program can cover much of that share for commercially insured patients.
Does the infusion site change the cost?
Yes. A hospital outpatient department adds a facility fee on top of the drug for every infusion, so over a full course a standalone infusion center or doctor’s office can save a significant amount. Ask your prescriber whether the infusions can be given at a lower-cost, in-network site.
What happens if my authorization is denied partway through?
A mid-course denial can leave you billed for infusions already given, so confirm prior authorization is approved before you start and watch for renewals. If a denial does create a bill, it is often appealable, and CareRoute Bill Defense can review and dispute it.
Related
Sources
- CMS Average Sales Price (ASP) drug pricing files (J2507 pegloticase)
- Amgen Krystexxa prescribing and dosing information
- Amgen Safety Net Foundation and Amgen copay program resources
- Health Care Cost Institute and AHA (hospital facility fees and site-of-care differentials)
Prices are national estimates for 2026 and vary by site and plan. Any change of infusion site or added medication is a decision for you and your prescriber. This page is educational and is not medical or financial advice. Last updated August 2026.